Pharmaceutical Technology

JUNE 29, 2022

In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market. By building upon its core competency, Novo Nordisk Pharmatech will begin serving the emerging regenerative medicine and advanced therapy markets through best-in-class speciality enzymes.

Drugs 295

Drugs Gene Therapy Manufacturing Production 295

Pharmaceutical Technology

MAY 2, 2023

There are more than 20 marketed ICIs with approvals across a very wide spectrum of solid tumour indications. Chimeric antigen receptor T-cell (CAR-T) therapies are the only genetically modified cell therapies to have received regulatory approval, and they are currently utilised in relapsed/refractory settings.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

pharmaphorum

MAY 7, 2021

CRISPR’s deal with Nkarta aims to create genetically engineered NK cells, which are harvested and used to create a bank of “off the shelf” cells that can administered to patients like a drug. CRISPR Therapeutics and Nkarta will equally share all R&D costs and profits worldwide related to the collaboration.

Gene Editing 52

Gene Editing Gene Genetic Engineering DNA 52

pharmaphorum

FEBRUARY 18, 2021

Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

The Pharma Data

JANUARY 17, 2021

Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Media Contact: Kelly Owen Grover Director of Marketing Communications 518-478-6095 kelly.grover@taconic.com . Source link.

Genetic Engineering 52

Genetic Engineering Genetics Engineer Immune Response 52

pharmaphorum

JANUARY 19, 2021

Marketed as Tecartus (autologous anti-CD19-transduced CD3+) in Europe, the drug was approved in the EU in December for adults with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.

Genetic Engineering 72

Genetic Engineering Engineer Genetics Drugs 72

XTalks

MARCH 6, 2024

This includes discussions on cutting-edge technologies and methodologies in brain research, such as neuroimaging, genetic engineering and artificial intelligence. Key market segments include drug types like antiepileptic, antipsychotic, antidepressant, cholinesterase inhibitors and NMDA receptor antagonists. percent.

FDA Approval 69

FDA Approval In-Vitro Research Marketing 69

pharmaphorum

AUGUST 23, 2021

DNA vaccines work by delivering a genetically-engineered plasmid containing the DNA sequence encoding the desired antigen – in this case the SARS-CoV-2 spike protein – which is then taken up by cells.

DNA 98

DNA Vaccination Vaccine Genetic Engineering 98

Advarra

JANUARY 11, 2024

Some of these approaches involve directly isolating the patient’s immune cells and simply expanding their quantity, while other treatments involve genetically engineering their immune cells to enhance cancer-fighting capabilities. Only after these trials are successful can sponsors seek market approval for mRNA-based products.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

Drug Discovery World

NOVEMBER 27, 2023

With more than 20 years of experience in business management, strategy, marketing, and product management, Anis also has research background from biotech, pharmaceutical, and premier academic organisations. Anis also serves on the scientific and editorial advisory board of Genetic Engineering News , Mary Ann Liebert, Inc.

Production 59

Production Engineer Gene Editing Gene 59

Pharmaceutical Technology

APRIL 5, 2023

More than a decade after the first patient was treated with a CAR-T therapy, six therapies relying on the same principles have been approved by the US Food and Drug Administration (FDA) and marketed to thousands of patients. Exa-cel is almost certainly going to the first CRISPR engineered product [to be approved].

Gene Therapy 147

Gene Therapy Gene Engineer Production 147

Drug Discovery World

MAY 7, 2024

RA: In recent years, what improvements have we seen to cell-line engineering for antibodies? DC: Antibodies have and remain a large product class within the biopharmaceutical market.

Antibody 59

Antibody Production Manufacturing Engineer 59

Drug Discovery World

FEBRUARY 14, 2024

Adding automation Recombinant protein vaccines, which are obtained by conventional genetic engineering, are based on the proteins of target pathogens that can activate our immune systems. However, such achievements can only be achieved by leveraging research strengths, regulatory capabilities and technical platforms.

Protein 59

Protein Vaccination Vaccine Manufacturing 59

Cloudbyz

MARCH 5, 2024

Market Exclusivity and Patents: Biologics are often protected by strong patent laws and regulatory data protection, which can provide longer periods of market exclusivity compared to small molecules. Such support can reduce the time and cost associated with bringing a new biologic to market.

Development 75

Development Drugs Manufacturing Immune Response 75

The Pharma Data

MARCH 29, 2022

In a preprint, the researchers at Cornell University led by Associate Professor Hector Aguilar-Carreno showed that genetically engineered mice infected with the virus causing COVID-19 and given a daily dose of the compound in a nasal spray for four days. WThe big picture is, there are multiple steps in the life cycle of a virus.

Genetic Engineering 52

Genetic Engineering Research Genetics Drugs 52

Drug Discovery World

JULY 5, 2023

Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent? MG: I am responsible for Agilent’s cancer segment.

Research 98

Research Protein Scientist Immune Response 98

The Pharma Data

APRIL 27, 2023

It is also an off-the-shelf therapy, meaning that people do not have to wait for cell collection and genetic engineering before starting treatment, which could be particularly important for patients who are at a high-risk of their disease progressing. A final decision is expected from the European Commission (EC) in the near future.

Genetic Engineering 40

Genetic Engineering Clinical Development Antibody Medicine 40

The Pharma Data

JULY 27, 2021

Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. About Teneobio Teneobio, Inc.

Production 52

Production Antibody Sales Manufacturing 52

The Pharma Data

OCTOBER 26, 2020

These mAbs are already of human origin and functionally optimized for high potency by the donor’s immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality.

Antibody 52

Antibody Genetic Engineering Development Clinical Trials 52

Drug Discovery World

NOVEMBER 17, 2022

The rapidly growing area of synthetic biology – including molecular biology, biotechnology, biophysics, and genetic engineering – is having a marked impact on the drug discovery landscape. SkyQuest Technology recently released a report: Global Synthetic Biology Market Insights, which highlights the sector’s value and potential.

Bacteria 52

Bacteria Engineer Gene Genetics 52

pharmaphorum

NOVEMBER 1, 2021

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer. million yen (around $12,500) per dose, according to a Pharma Japan report.

Genetic Engineering 122

Genetic Engineering Clinical Trials Clinical Trials Trials 122

Roots Analysis

MARCH 16, 2023

The IVT mRNAs are structurally similar to natural mRNAs, these synthetic mRNAs can be used to express proteins through genetic engineering. What are the key trends that are shaping up the mRNA therapeutics and vaccines market? mRNA-based therapeutics and vaccines can be delivered via the below-mentioned approaches.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

The Pharma Data

NOVEMBER 4, 2020

. Relying on independent research and development, the Company has formed gene recombination and fermentation engineering technology, and developed a number of core technologies, such as recombinant collagen, enzymatic and genetic engineering synthesis of bioactive peptides.

Licensing 40

Licensing Licensing Dermatology Production 40

Roots Analysis

FEBRUARY 13, 2023

It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein. With the help of genetic engineering, synthetic mRNAs can express proteins, as they structurally resemble a natural mRNA.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

XTalks

SEPTEMBER 15, 2022

According to the order, it will improve and expand biomanufacturing production capacity and processes, train a biotech workforce, expand market opportunities for these products and streamline regulation. The federal law that mandates some genetically modified (GM) food and beverage items to be labeled calls them “bioengineered.”

FDA Approval 95

FDA Approval Genetic Engineering Genetics Production 95

Drug Discovery World

JULY 22, 2022

Additionally, myeloid supportive HIS models that express hIL3 and human granulocyte macrophage colony stimulating factor (hGM-CSF) can be repurposed to explore current and theoretical therapies on the clinical market, such as dendritic cell (DC) and macrophage-based therapies. Volume 23 – Issue 3, Summer 2022. About the author.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

The Pharma Data

SEPTEMBER 8, 2020

Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs. For more information, visit. www.novavax.com. and connect with us on.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

Advarra

JUNE 13, 2023

Research in gene therapies and genetically engineered drugs and vaccines are growing exponentially, and will only continue to become more popular. The accelerating gene therapy market is expected to grow globally by 16.6% between 2020-2027.

Gene Therapy 52

Gene Therapy Gene Research Genetic Engineering 52

pharmaphorum

SEPTEMBER 13, 2022

Thanks to the dedicated efforts of doctors, patients, carers, and healthcare professionals, people diagnosed with blood cancer are now living longer, with a steady stream of more effective treatments entering the market each year. 2016–2022 — New treatments enter the market. 1832 – Discovery of Hodgkin’s and non-Hodgkin’s lymphoma.

Genome Project 98

Genome Project Genome Genomics DNA 98

Roots Analysis

FEBRUARY 15, 2022

Gene engineering based on recombination was pioneered in the mid-1990s; Currently, development of gene editing technologies has opened up the possibility of modifying genomic sequences in both eukaryotic and prokaryotic organisms. Bringing in Light Genome Editing Techniques: ZFN, TALEN and Meganucleases. Our Social Media Platform.

Genome 52

Genome Genomics Gene Editing DNA 52

Roots Analysis

OCTOBER 22, 2023

It is important to highlight that IVT mRNAs are structurally similar to natural mRNAs and can be used to express proteins through genetic engineering. In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent.

RNA 40

RNA Protein Genetics Gene Expression 40

pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Though advances in genetic engineering have greatly supported high-producing cell lines, the successful development of bsAbs at scale relies on the genetic stability of such lines.

Antibody 52

Antibody Immune Response Production Engineer 52

Drug Discovery World

MARCH 13, 2023

The individual successes within the CGT market are impressive, but this therapeutic class remains unattainable to the vast majority of the world. Drug discovery researchers usually partner with a CDMO to provide support through the development, manufacturing, and clinical supply required to bring a drug to market. August 2020.

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52

Drug Discovery World

FEBRUARY 15, 2023

Rising demand The global immuno-oncology assay market is expected to grow at a compound annual growth rate (CAGR) of 11.87% from 2021 to 2030 to reach 11.74bn USD by 2030 7. Strategic Market Research Report; Immuno-oncology Assays Market Size, Trend Analysis 2030. Korman, A. & Allison, J. 90, 297–339 (2006).

Research 52

Research In-Vitro In-Vivo Development 52

The Pharma Data

OCTOBER 27, 2020

The decrease in Adcirca revenues was driven by continued erosion of market share due to generic competition. Sales and marketing. Cash, cash equivalents, and marketable investments. Cost of product sales. Dollar Change. .

Production 40

Production Sales Licensing Licensing 40